FollowMyHealth Patient Portal

Brian Van Tine, MD, PhD

Assistant Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Oncology
Sarcoma
Medical Oncology

Board Certifications

Internal Medicine
Medical Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Medical oncology, cancer, sarcoma, soft tissue sarcoma, bone cancer, leiomyosarcoma, liposarcoma

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171

Education

Education

Medical Degree: University of Alabama at Birmingham 2005
PhD: University of Alabama at Birmingham 2003
Chief Fellow: Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri 2010
BS: University of Arizona, Tucson, Arizona 1995
Residency: Barnes-Jewish Hospital, St. Louis, Missouri 2006
Fellowship: Oncology, Washington University School of Medicine, St. Louis, Missouri 2007

Publication & Research

Publication & Research

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM
Am J Hematol. 2018 Jan 20; doi: 10.1002/ajh.25043.

PMID:
    29352732
    [PubMed - as supplied by publisher]
Related citations


Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS
Cell Death Dis. 2018 Jan 5; 9(1)5. doi: 10.1038/s41419-017-0029-0.

PMID:
    29305574
    [PubMed - in process]
Related citations


Synovial Sarcoma: Current Concepts and Future Perspectives.
Stacchiotti S, Van Tine BA
J Clin Oncol. 2018 Jan 10; 36(2)180-187. doi: 10.1200/JCO.2017.75.1941.

PMID:
    29220290
    [PubMed - in process]
Related citations


Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience.
Cosper PF, Olsen J, DeWees T, Van Tine BA, Hawkins W, Michalski J, Zoberi I
Radiat Oncol. 2017 Dec 8; 12(1)198. doi: 10.1186/s13014-017-0920-y.

PMID:
    29216884
    [PubMed - in process]
Related citations


Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca., Cancer Genome Atlas Research Network.
Cell. 2017 Nov 2; 171(4)950-965.e28. doi: 10.1016/j.cell.2017.10.014.

PMID:
    29100075
    [PubMed - indexed for MEDLINE]
Related citations


Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S
Lancet Oncol. 2017 Nov; 18(11)1493-1501. doi: 10.1016/S1470-2045(17)30624-1.

PMID:
    28988646
    [PubMed - indexed for MEDLINE]
Related citations


Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S
J Clin Oncol. 2017 Oct 20; 35(30)3433-3439. doi: 10.1200/JCO.2016.71.6605.

PMID:
    28854066
    [PubMed - indexed for MEDLINE]
Related citations


Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.
Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyö D, Held JM
Sci Signal. 2017 Aug 8; 10(491)pii: eaam8065. doi: 10.1126/scisignal.aam8065.

PMID:
    28790197
    [PubMed - in process]
Related citations


Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.
Oppelt PJ, Hirbe AC, Van Tine BA
J Gastrointest Oncol. 2017 Jun; 8(3)466-473. doi: 10.21037/jgo.2016.09.15.

PMID:
    28736634
    [PubMed]
Related citations


Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P
Lancet Oncol. 2017 Aug; 18(8)1089-1103. doi: 10.1016/S1470-2045(17)30381-9.

PMID:
    28651927
    [PubMed - indexed for MEDLINE]
Related citations


Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect.
Kremer JC, Van Tine BA
Mol Cell Oncol. 2017; 4(3)e1295131. doi: 10.1080/23723556.2017.1295131.

PMID:
    28616574
    [PubMed]
Related citations


Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.
Hirbe AC, Cosper PF, Dahiya S, Van Tine BA
Sarcoma. 2017; 20173761292. doi: 10.1155/2017/3761292.

PMID:
    28546782
    [PubMed]
Related citations


Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS.
Whyte MP, Griffith M, Trani L, Mumm S, Gottesman GS, McAlister WH, Krysiak K, Lesurf R, Skidmore ZL, Campbell KM, Rosman IS, Bayliss S, Bijanki VN, Nenninger A, Van Tine BA, Griffith OL, Mardis ER
Bone. 2017 Aug; 101145-155. doi: 10.1016/j.bone.2017.04.010.

PMID:
    28434888
    [PubMed - in process]
Related citations


Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA
Cell Rep. 2017 Jan 24; 18(4)991-1004. doi: 10.1016/j.celrep.2016.12.077.

PMID:
    28122247
    [PubMed - indexed for MEDLINE]
Related citations


A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
Agulnik M, Costa RLB, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA
Ann Oncol. 2017 Jan 1; 28(1)121-127. doi: 10.1093/annonc/mdw444.

PMID:
    27771610
    [PubMed - indexed for MEDLINE]
Related citations


A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA
Cell Death Dis. 2016 Oct 13; 7(10)e2406. doi: 10.1038/cddis.2016.232.

PMID:
    27735949
    [PubMed - indexed for MEDLINE]
Related citations


PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P
J Clin Oncol. 2016 Nov 10; 34(32)3898-3905. doi: 10.1200/JCO.2016.67.6684.

PMID:
    27621408
    [PubMed - indexed for MEDLINE]
Related citations


Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK
Ann Oncol. 2016 Oct; 27(10)1855-60. doi: 10.1093/annonc/mdw281.

PMID:
    27502708
    [PubMed - indexed for MEDLINE]
Related citations


Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK
Lancet. 2016 Jul 30; 388(10043)488-97. doi: 10.1016/S0140-6736(16)30587-6.

PMID:
    27291997
    [PubMed - indexed for MEDLINE]
Related citations


Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG
Oncotarget. 2016 Jun 7; 7(23)33529-41. doi: 10.18632/oncotarget.9551.

PMID:
    27244881
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2016.

Company Name: Jansen & Jansen

Royalties:

Equity: No

Consulting/Advisory Board:

Speaker Fees: $10,001 - $25,000

Reporting Date: May 01, 2017

Areas of Research Interest

Our focus is on understanding the genomics of osteosarcoma, leiomyosarcoma and rarer forms of sarcoma. Using mouse genetics, human tumor xenografting and cancer biology we strive to identify druggable targets that can be used in the clinic.